Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Washington, DC, March 19, 2026 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA), as well as leading allergy medical societies the American Academy of Allergy,...
-
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
-
Approval in Costa Rica for Kinesiology Tape Products
-
SK pharmteco today announced the successful conclusion of a regulatory inspection of its small molecule North America facility in La Porte, Texas.
-
Solve GNE highlights new research, expanded funding efforts, and progress toward a Phase I clinical trial for GNE myopathy.
-
TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...
-
MORRISTOWN, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Piston Bio LLC, a clinical-stage biotechnology company developing therapeutics targeting neuroimmune mechanisms in cancer, today announced the...
-
Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
-
Sangamo has now submitted the ST-920 preclinical and clinical modules to the FDA for review.
-
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for...